Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

histoplasmosis - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

histoplasmosis

MONDO:0018312

Also known as:Histoplasma caused disease or disorderHistoplasma disease or disorderHistoplasma infectious disease

Find Clinical TrialsTrials

Overview

A disease caused by the fungus Histoplasma capsulatum. It primarily affects the lungs but can also occur as a disseminated disease that affects additional organs. The acute respiratory disease has symptoms similar to those of a cold or flu and it usually resolves without treatment in healthy individuals. The disseminated form is generally fatal if untreated.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials1 registered

Diagnosis

Biomarker and diagnostic research for histoplasmosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for histoplasmosis. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for histoplasmosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for histoplasmosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE3. Research is primarily sponsored by academic and government institutions.

324 publications have been identified in PubMed for histoplasmosis. Research spans Case Report / Case Series (37%), Epidemiology / Natural History (21%), and Review / Meta-Analysis (17%).

Research Type	Count	% of Total
Patient case studies	121	37%

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:53 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:390

GARD

Genetic and Rare Diseases Info Center

GARD:18692

Questions for Your Care Team

→Are any of the 1 active clinical trial a good fit for my situation?
→What is the current development status of Liposomal amphotericin B, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

histoplasmosis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Secondary Hemophagocytic lymphohistiocytosis in an immunocompetent adult: a case report distinguishing sarcoidosis from histoplasmosis.

Delayed diagnosis of primary cutaneous histoplasmosis in a patient receiving tumour necrosis factor alpha inhibitor therapy.

Histoplasmosis-Associated Hemophagocytic Lymphohistiocytosis Presenting as Pyrexia of Unknown Origin With Splenic Masses.

histoplasmosis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Secondary Hemophagocytic lymphohistiocytosis in an immunocompetent adult: a case report distinguishing sarcoidosis from histoplasmosis.

Delayed diagnosis of primary cutaneous histoplasmosis in a patient receiving tumour necrosis factor alpha inhibitor therapy.

Histoplasmosis-Associated Hemophagocytic Lymphohistiocytosis Presenting as Pyrexia of Unknown Origin With Splenic Masses.